In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
VistaGen Therapeutics's net current asset value per share for the quarter that ended in Dec. 2021 was $0.37.
The historical rank and industry rank for VistaGen Therapeutics's Net Current Asset Value or its related term are showing as below:
VTGN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.52 Med: 7.33 Max: 65.33
Current: 3
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of VistaGen Therapeutics was 65.33. The lowest was 2.52. And the median was 7.33.
VTGN's Price-to-Net-Current-Asset-Value is ranked better than 50.04% of 1219
companies
in the Biotechnology industry
Industry Median: 3.08
vs VTGN: 3.00
VistaGen Therapeutics Net Current Asset Value Historical Data
The historical data trend for VistaGen Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Net Current Asset Value
0.03
0.29
0.16
-0.20
0.49
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Net Current Asset Value
0.65
0.49
0.43
0.39
0.37
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Net Current Asset Value, along with its competitors' market caps and Net Current Asset Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Net Current Asset Value Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Net Current Asset Value distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Net Current Asset Value falls into.
VistaGen Therapeutics Net Current Asset Value Calculation
VistaGen Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of GrahamÂ’s strategy produced similar results.
VistaGen Therapeutics Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(2.63%) Volume: 698,624 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
